Haematology and Leukaemia - Senior Research Staff - Dr David Izon

Dr David Izon

Unit Head

Education and Professional Experience

BSc (Hons) Monash University
PhD Monash University
1990-91     Fogarty Research Fellow, Biological Response Modifiers Program, NIH
1991-94     Division of Immunology, The Netherlands Cancer Institute, Amsterdam
1994-95     MRC Clinical Sciences Centre, Hammersmith Hospital, London
1996-97     Department of Hematology, Veteran's Affairs Medical Center, San Francisco
1998          Dept.Pathology and Immunology Monash Medical School, Vic. Australia
1998-99     Staff Scientist, The Wistar Institute,Philadelphia, PA.
1999-01     Senior Post-Doctoral Fellow, Dept Pathology, University of Pennsylvania
2001-03     Co-Head, Cancer Biology Division, Telethon Institute for Child Health Research
2004-05     Head, Cancer Biology Division, Telethon Institute for Child Health Research
2006-         Head, Haematology and Leukaemia Division, St. Vincent's Institute

Achievements

.

Research Interests

T cell differentiation and leukaemiaOther areas of interest - Haemopoiesis and leukaemia

The main research theme centres around T cell development and how studying this can help identify the causes of T cell leukaemia. As a result we are attempting to identify new T cell oncogenes. We are addressing this problem by utilising a retroviral cDNA library screening method in primary mouse cells.

Additionally, we are creating leukaemic mouse models of other blood cell lineages using retroviral overexpression. In order to analyse leukaemic mouse models we use multiparameter flow cytometry and cell sorting.

Selected Publications

  1. Boyd, R.L., Tucek, C.L., Godfrey, D.I., Izon, D.J., Wilson, T.W., Davidson, N.J., Bean, A.G.D., Ladyman, H.M., Ritter, M.A. and Hugo, P. 1993. The thymic microenvironment. Immunol. Today. 14, 445-459.
  2. Bain, G., Robanus-Maandag, E.C., Izon, D.J., Amsen, D., Kruisbeek, A.M., Weintraub, B., Krop, I., Schissel, M.S., Feeney, A.J., van Roon, M., van der Walk, M., te Riele, H.P.J., Berns, A. and Murre, C. 1994. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell. 79, 885-892.
  3. Verbeek, S , Izon, D.J., Hofhuis, F., Robanus-Maandag, E., te Riele, H., van de Wetering, M., Oosterwegel, M., Wilson, A., MacDonald, H.R., and Clevers, H.1995. Requirement of HMG Box factor Tcf-1 for thymocyte differentiation. Nature. (London), 374, 70-74.
  4. Izon, D.J., Rozenfeld, S., Fong, S., Komuves, L.G., Largman, C., and Lawrence, H.J. 1998. Loss of function of the homeobox gene Hoxa-9 perturbs early T cell development and induces apoptosis in primitive thymocytes. Blood. 92: 383-393.
  5. Izon, D.J., Punt, J.A., Xu, L., Karnell, F.G., Allman, D., Myung, P.S., Boerth, N.J., Pui, J.C. Koretzky, G.A. and Pear, W.S. 2001. Notch1 regulates maturation of CD4+ and CD8+ thymocytes by modulating TCR signal strength. Immunity.14:253-264.
  6. Izon, D.J., Rudd, K., DeMuth, W., Pear, W.S., Clendenin, C., Lindsley, R.C., and Allman, D. 2001. A common pathway for dendritic cell and B cell development. J.Immunol. 167:1387-1392.
  7. Izon, D.J., Aster, J.C., He, Y., Weng, A ., Karnell, F.G., Patriub, V., Xu, L., Bakkour, S., Rodriguez, C., Allman, D., and Pear, W.S. 2002. Deltex1 redirects lymphoid progenitors to the B cell lineage by antagonizing Notch1. Immunity.16:231-243.
  8. Izon, D.J, Punt, J.A., and Pear, W.S. 2002. Deciphering the role of Notch signaling in lymphopoiesis. Curr. Op. Imm. 14:192-199.
  9. Allman, D., Punt, J.A., Izon, D.J., Aster, J.C., and Pear, W.S. 2002. An invitation to T and more: Notch signaling in lymphopoiesis. Cell. 109, (SO2):S1-11.
  10. Miller, J.P., Izon, D.J., Gerstein, R., Bhandoola, A., and Allman, D. 2002. Interleukin-7 is sufficient and essential for early B-lineage differentiation from common lymphoid progenitors. J. Exp. Med. 196: 705-711.
  11. Goethert,J.R., Gustin. S.E., J. van Eekelen, A.M., Schmidt, U., Hall, M.A., Jane, S.M. Green, A.R., Gottgens, B., Izon, D.J., and Begley, C.G. 2004. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood.104:1769-77 12.Goethert,J.R., Gustin, S.E., Green, A.R., Gottgens, B., Izon, D.J., and Begley, C.G. 2005. Temporally controlled transgenic targeting with the SCL stem cell enhancer: fate tracing embryonic hematopoietic stem cells into adulthood. Blood.105:2724-2732.